INTRODUCTION

Non-24-hour sleep-wake disorder (N24SWD) is a relatively rare disorder that is often observed in the visually impaired and those who isolate indoors. In addition to lifestyle guidance and high-intensity light therapy, the use of vitamin B12 and sleeping pills is recommended for treatment. However, with regard to hypnotics, benzodiazepine hypnotics have almost no effect on human biological rhythms themselves; thus, a therapeutic effect of a benzodiazepine hypnotic alone cannot be expected. Ramelteon, a melatonin receptor agonist, reverses a shifted sleep phase back to normal. However, the usefulness of ramelteon in N24SWD has not been shown so far. N24SWD is a disease that significantly impairs the patient’s quality of life, and it is expected that a treatment method will be established in the future. Here, we report a case of autism spectrum disorder (ASD) with N24SWD successfully treated with a combination of ramelteon and suvorexant.

CASE

A 23-year-old sighted woman visited our hospital seeking treatment for a delayed sleep phase disorder that progressed each day. Her development was not typical. Since early childhood, although her mother darkened the room to put her to sleep, she was active and found it difficult to sleep at night. She had difficulty getting up in...
the morning but was able to attend school. When her mother called her, she sometimes gave no reply; thus, the mother initially thought she was deaf, but she was not. She covered her ears when watching TV, which might mean hypersensitivity. Because she tried to stick to her own interpretations and methods, her mother thought of her as a difficult child to raise. However, in junior high school, she was left out of her group of friends and was unable to attend school. There was no noticeable bullying but she later attended a special classroom, after which she went to a correspondence high school. She entered college, left her parents, and lived with her sister. However, she often felt anxious, calling her mother with a pessimistic view of life and said that "I hate living." She was so embarrassed to write her thoughts on a class report that she could not submit it and dropped out of college. Since then, she has lived at her parents' home, sometimes helping with housework. After dropping out of college, her sleeping hours became different day by day and her circadian rhythm was often completely reversed. Initially, she was sleepy but could not sleep for approximately 2 hours when she went to bed. The sleep cycle is now delayed by one cycle every 20 to 30 days (approximately every 25 days). She tried to control herself for 3 to 4 years but could not do so; therefore, she visited our hospital. She brought her sleep records to date, which show that she had six of these delayed cycles in 154 days; thus, her sleep rhythm averaged one of these cycles every 25.6 days (Figure 1).

She was diagnosed with ASD using the Diagnostic and Statistical Manual of Mental Disorders version 5, characterized by persistent challenges with social communication and social interaction, and by the presence of restricted, repetitive patterns of behavior, interests, or activities. Additionally, using International Classification of Sleep Disorders (ICSD) criteria, she was diagnosed with N24SWD. She had no other notable physical illnesses.

She received behavioral education, but her sleep rhythm did not improve. Then, we initiated treatment with 8 mg of ramelteon every night around 11:00 PM, and the N24SWD cycle was extended from 25.6 days to 42 days, but did not completely recover. Therefore, we added 15 mg of suvorexant, and the sleep rhythm was restored (Figure 1). Subsequently, she began to take steps to go outside and can now go to a social rehabilitation facility once or twice a week.

3 | DISCUSSION

We herein report a case of a patient with ASD who suffered from N24SWD. To our knowledge, this is the first report of successful treatment with a combination of ramelteon and suvorexant to a sighted patient with ASD with N24SWD.

ASD is a neurodevelopmental disorder characterized by impairments in communication skills and social interaction, as well as restricted, repetitive, and stereotyped patterns of behavior. Among the most common comorbidities in ASD, sleep disorders occur in 40% to 80% of cases, which exceeds the 20% to 40% in children with typical development. The presence of sleep

Figure 1

In September, we initiated behavioral education but, owing to a lack of improvement, we prescribed ramelteon 8 mg from the end of September. Although the N24SWD cycle was extended from 25.6 to 42 d, the patient did not completely recover. Thus, we added 15 mg of suvorexant, and the sleep rhythm was restored [Colour figure can be viewed at wileyonlinelibrary.com]
disorders in individuals with ASD may exacerbate associated behavioral disorders and lead to the intensification of existing autonomic symptoms. Among the etiological hypotheses, atypical production of melatonin may explain the high prevalence of sleep disorders in ASD.

Our case was a patient with ASD who displayed more severe symptoms after dropping out of college. When she was at school, she managed to maintain a standard sleep cycle but N24SWD became apparent once she stopped going outside.

N24SWD is a relatively rare condition that is characterized by a chronic steady pattern of approximately 1-hour delays in spontaneous sleep-onset and wake times in individuals living under normal environmental conditions. For example, for a patient who is delayed by 1 hour every day, the day for the patient is 24 hours + 1 hour = 25 hours. It is difficult to fall asleep at a certain time and wake up in the morning. Eventually, a complete day-night reversal occurs; thus, approximately every month, social life is disturbed owing to insomnia at night and excessive sleepiness during the day. Patients who try to maintain a constant sleeping time often complain of periodic insomnia and difficulty waking. If a patient wakes up during day sleep hours, they may experience drowsiness, decreased attention, difficulty in maintaining concentration, fatigue, and malaise. A diagnosis can be achieved by recording sleep diaries and clarifying sleep/wake patterns.

N24SWD is defined according to four ICSD-3 criteria: (a) history of insomnia, excessive daytime sleepiness, or both, which alternate with asymptomatic episodes, owing to misalignment between the 24-hour light-dark cycle and the nonentrained endogenous circadian rhythm of sleep-wake propensity; (b) symptoms persist over the course of at least 3 months; (c) daily sleep logs and actigraphy for at least 14 days, preferably longer for blind persons, demonstrate a pattern of sleep and wake times that typically delay each day, with a circadian period that is usually longer than 24 hours; and (d) the disorder is not better explained by another current sleep disorder, medical or neurological disorder, mental disorder, and substance use disorder.

At least 50% of totally blind persons (ie, those with no light perception) are thought to suffer from the disorder. Although the etiology in the blind is a loss of photic input to the pacemaker, the pathophysiology among sighted individuals is unknown.

No visual impairment was observed in our case, but the symptoms of N24SWD became apparent after the patient dropped out of college and stayed inside the home. In a report by Watanabe et al, the symptoms of N24SWD also became apparent owing to a major life event, in which the patient quit his job in search of a new one.

There are few effective treatments for N24SWD. As benzodiazepine hypnotics have almost no effect on human biological rhythms themselves, they cannot be expected to be effective alone in the treatment of N24SWD; however, they may be effective when used in combination with high-intensity phototherapy. The administration of melatonin may be effective for N24SWD in blind but not sighted patients. The only drug that is indicated for N24SWD is tasimelteon, a selective agonist of the melatonin receptors MT₁ and MT₂, which can be prescribed in the United States and Europe.

Ramelteon is also a sleep agent that selectively binds to the MT₁ and MT₂ receptors. Ramelteon is efficacious in the treatment of insomnia characterized by difficulty with sleep onset and, as ramelteon is an agonist of the melatonin receptor that controls sleep rhythm, it is expected to have an effect on sleep rhythm disorders.

Melatonin agonists, such as ramelteon, are thought to act on the circadian clock in the suprachiasmatic nucleus of the hypothalamus via the activation of endogenous melatonin receptors. In our case, the oral administration of ramelteon improved the circadian rhythm but its effect was insufficient. However, with the addition of suvorexant, it is possible to secure a sleep rhythm to the extent that daily life can be carried out and social participation becomes possible.

Suvorexant is an orexin receptor antagonist being developed for the treatment of insomnia. Extensive research has demonstrated that the orexin system plays a critical role in the regulation of the transition between sleep and arousal, especially inducing wakefulness. Therefore, suvorexant may have improved sleep-wake rhythm by suppressing the part of wakefulness.

Although it has already been reported that ramelteon can improve N24SWD, the best of our knowledge, there are not many reports of the therapeutic effects of ramelteon on N24SWD and no randomized controlled or large clinical trials. In our case, ramelteon extended her N24SWD cycle but not by enough. Further, we have shown that suvorexant may be an adjunctive treatment to improve sleep cycles with ramelteon.

Thus far, the effectiveness of suvorexant against N24SWD has not been reported; however, it remains possible that suvorexant monotherapy is effective against N24SWD.

A recent paper found that the orexin nerves express MT₁ receptors but not MT₂ receptors in the perifornical lateral hypothalamus. It was also suggested that melatonin inhibits orexin neurons via MT₁ receptors, thereby promoting sleep. Thus, suvorexant, an orexin receptor antagonist, enhances the effect of ramelteon on MT₁ stimulation. Among the melatonin receptors, the stimulation of MT1 receptors causes the suppression of nerve firing, whereas the stimulation of MT₂ receptors is known to have a sleep phase-advancing effect. As suvorexant does not appear to be associated with MT₂ action, sleep phase advance is not expected; thus, the effect of suvorexant monotherapy on N24SWD remains questionable.

In our case, the effect of ramelteon on circadian rhythm modification was observed, as evident from the extension in the N24SWD cycle from 25.6 days to 42 days following ramelteon administration. Pharmacologically, this is mainly attributed to ramelteon; however, in our case, the sleep phase-advancing effect of ramelteon and the neuroleptic suppressive effect of suvorexant might have acted synergistically. Further research is expected in the future.
4 | CONCLUSION

We present a case in which the combination therapy of ramelteon and suvorexant was effective for a patient with ASD with N24SWD owing to social withdrawal. Ramelteon exhibits an agonistic effect on melatonin MT1 and MT2 receptors, as does tasimelteon; therefore, ramelteon may be as effective as tasimelteon, which has an effect on N24SWD. However, melatonin receptor agonists have not been fully demonstrated to be effective in patients without visual impairment. Based on our results, we propose a combination of ramelteon and suvorexant as a possible therapeutic strategy for sighted patients with N24SWD.

ACKNOWLEDGMENTS

We would like to thank the patient for allowing the publication of this report and editage for English language editing.

CONFLICT OF INTEREST

M. I. received honoraria as a speaker from MSD KK KK declares no conflict of interest.

AUTHOR CONTRIBUTIONS

M. I. treated the patient and drafted the manuscript. K. K. critically reviewed the draft and revised it. All authors made substantial contributions, drafted the manuscript, and approved the final manuscript.

INFORMED CONSENT

Informed consent was obtained from the patient.

DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

ORCID

Masaaki Iwata https://orcid.org/0000-0002-6143-0181

REFERENCES

1. Malkani RG, Abbott SM, Reid KJ, Zee PC. Diagnostic and Treatment Challenges of Sighted Non-24-Hour Sleep-Wake Disorder. J Clin Sleep Med. 2018;14:603–13.
2. Quera Salva MA, Hartley S, Léger D, Dauvilliers YA. Non-24-Hour Sleep-Wake Rhythm Disorder in the Totally Blind: Diagnosis and Management. Front Neurol. 2017;8:868.
3. Garbazza C, Bromundt V, Eckert A, Brunner DP, Meier F, Hackethal S, et al. Non-24-Hour Sleep-Wake Disorder Revisited - A Case Study. Front Neurol. 2016;7:17.
4. Kurita M, et al. Non-24-hour sleep-wake syndrome improved by low-dose valproic acid: a case report. Neuropsychiatr Dis Treat. 2016;12:3199–203.
5. Ohta T. Circadian rhythm sleep disorders: a brief review with special reference to long-term follow-up. Nagoya J Med Sci. 1995;58:83–93.
6. Yamadera W, Sasaki M, Itoh H, Ozone M, Ushijima S. Clinical features of circadian rhythm sleep disorders in outpatients. Psychiatry Clin Neurosci. 1998;52:311–6.
7. Auger RR, Burgess HJ, Emens JS, Deriy LV, Thomas SM, Sharkey KM. Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep-Wake Rhythm Disorder (N24SWD), and Irregular Sleep-Wake Rhythm Disorder (ISWRD). An Update for 2015. J Clin Sleep Med. 2015;11(10):1199–236.
8. Atkin T, Comai S, Gobbi G. Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. Pharmacol Rev. 2018;70:197–245.
9. Melke J, Goubran Botros H, Chaste P, Betancur C, Nygren G, Anckarsäter H, et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry. 2008;13:90–8.
10. Zuculo GM, Gonçalves BSB, Brittes C, Menna-Barreto L, Pinao L. Melatonin and circadian rhythms in autism: Case report. Chronobiol Int. 2017;34:527–30.
11. Tudor ME, Walsh CE, Mulder EC, Lerner MD. Pain as a predictor of sleep problems in youth with autism spectrum disorders. Autism. 2015;19:292–300.
12. Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res. 2012;21:700–9.
13. Fadini CC, Lamónica DA, Fett-Conte AC, Osório Elaine, Zuculo GM, Giachetti CM, et al. Influence of sleep disorders on the behavior of individuals with autism spectrum disorder. Front Hum Neurosci. 2015;9:347.
14. Glickman G. Circadian rhythms and sleep in children with autism. Neurosci Biobehav Rev. 2010;34:755–68.
15. Johnson KP, Giannotti F, Cortesi F. Sleep patterns in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am. 2009;18:917–28.
16. Hayakawa T, Uchiyama M, Kamei Y, Shibui K, Tagaya H, Asada T, et al. Clinical analyses of sighted patients with non-24-hour sleep-wake syndrome: a study of 57 consecutively diagnosed cases. Sleep. 2005;28:945–52.
17. American Association of Sleep Medicine Darien, IL. 2014.
18. Sack RL, Lewy AJ, Blood ML, Keith LD, Nakagawa H. Circadian rhythm abnormalities in totally blind people: incidence and clinical significance. J Clin Endocrinol Metab. 1992;75:127–34.
19. Czeisler CA, Shanahan TL, Klerman EB, Martens H, Brotman DJ, Emens JS, et al. Suppression of melatonin secretion in some blind patients by exposure to bright light. N Engl J Med. 1995;332:6–11.
20. Watanabe A, Hirose M, Arakawa C, Iwata N, Kitajima T. A Case of Non-24-Hour Sleep-Wake Rhythm Disorder Treated With A Low Dose of Ramelteon and Behavioral Education. J Clin Sleep Med. 2018;14:1265–7.
21. Williams WP, McLin DE, Dressman MA, Neubauer DN. Comparative review of approved melatonin agonists for the treatment of circadian rhythm sleep-wake disorders. Pharmacotherapy. 2016;36:1028–41.
22. Lockley SW, Dressman MA, Licamele L, Xiao C, Fisher DM, Flynn-Evans EE, et al. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet. 2015;386:1754–64.
23. Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013;36:259–67.
24. Zeitzer JM, Joyce DS, McBea A, Quevedo YL, Hernandez B, Holty JE. Effect of Suvorexant vs Placebo on Total Daytime Sleep Hours in Shift Workers: A Randomized Clinical Trial. JAMA Netw Open. 2020;3:e200664.
25. Mieda M, Hasegawa E, Kisanuki YY, Sinton CM, Yanagisawa M, Sakurai T. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J Neurosci. 2011;31:6518–26.
26. Sharma R, Sahota P, Thakkar MM. Melatonin promotes sleep in mice by inhibiting orexin neurons in the perifornical lateral hypothalamus. J Pineal Res. 2018;65:e12498.

27. Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997;19:91–102.

28. Dubocovich ML, Yun K, Al-Ghoul WM, Benloucif S, Masana MI. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J. 1998;12:1211–20.

How to cite this article: Iwata M, Kaneko K. Non-24-hour sleep-wake disorder successfully treated with the combination of ramelteon and suvorexant in a case of autism spectrum disorder. Neuropsychopharmacol Rep. 2020;40:383–387. https://doi.org/10.1002/npr2.12142